日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

New vaccine protects the previously infected

By WANG XIAOYU | China Daily | Updated: 2021-09-24 09:59
Share
Share - WeChat
Taxi driver Zheng Ruiwen (front) puts on a protective gown before setting off to transport COVID-19 nucleic acid samples in Putian, Fujian province, on Sept 23, 2021. [Photo by ZHANG BIN/CHINA NEWS SERVICE]

Chinese biotechnology company Clover Biopharmaceuticals said on Wednesday that a large trial shows its two-dose COVID-19 vaccine is 79 percent effective against the fast-spreading Delta variant, which was first detected in India.

The vaccine candidate is 92 percent effective against the Gamma variant first identified in Brazil, and 59 percent against the Mu variant first detected in Colombia, according to joint statement issued by the company and the Coalition for Epidemic Preparedness Innovations, a nonprofit organization that funded the clinical trial.

The vaccine's overall efficacy rate against all strains in the study was 67 percent. It was also 100 percent effective in preventing severe cases and hospitalizations, and nearly 84 percent effective in preventing moderate to severe cases, the statement said.

The vaccine is the "first COVID-19 vaccine to demonstrate significantly reduced risk of COVID-19 disease in previously infected individuals, a growing and increasingly important population as SARS-CoV-2(the novel coronavirus that causes the disease) continues to spread globally", it said.

The protein-based vaccine uses protein fragments of the virus to trigger immune responses, and requires the use of an adjuvant to achieve desired protection.

Clover Biopharmaceuticals, which is based in Chengdu, Sichuan province, said its adjuvant is supplied by the US company Dynavax.

More than 30,000 adults-some of them elderly-in the Philippines, Brazil, Colombia, South Africa and Belgium were enrolled in mid- and late-stage clinical trials. They were either given two doses administered 21 days apart or a placebo.

Like the inactivated vaccines widely deployed in China, the experimental vaccine can be stored at regular refrigerated temperatures of 2 to 8 C, making its transportation and distribution easier.

The company said it plans to submit applications for conditional market approval to global regulatory authorities in the fourth quarter of the year and is aiming for a potential market launch by the end of the year.

Clover Biopharmaceuticals is also a supplier to COVAX, an international initiative that distributes vaccines to low- and middle-income countries.

The company signed an advance purchase agreement with Gavi, one of the co-leaders of COVAX, in late June to provide 414 million doses of its vaccine to the initiative by next year.

However, the product has to first gain emergency use authorization from the World Health Organization, which is anticipated in the fourth quarter of this year, according to Gavi.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 看免费大片 | 99自拍视频在线观看 | 天天草夜夜操 | 国产精品视频网 | 欧美成人激情在线 | 不卡的av在线 | 欧洲成人午夜免费大片 | 欧美成人a级在线视频 | 三级理伦 | 欧美精品一区二区蜜臀亚洲 | 久久日韩精品中文字幕网 | 国产黄在线观看免费观看软件视频 | 日韩精品一区二区三区国语自制 | 日本a级大片 | 久久久久免费观看 | 日本高免费观看在线播放 | www.成人.com | 人人爽人人看 | 欧美一区二区在线播放 | 久久精品小短片 | 奇米影视在线播放 | 一区二区三区视频免费观看 | 日韩中文字幕网站 | 1级毛片| 亚洲成人日韩 | 舒淇三级浴室洗澡在线观看 | 伊人青青操 | 亚洲九九 | 夜夜撸.com | 久久香蕉国产线熟妇人妻 | 亚洲黑人在线观看 | 久久久国产一区二区三区 | 中文字幕自拍偷拍 | 色网址在线| 欧美在线观看视频一区 | 日日操夜夜 | 天天天操 | 免费网站看v片在线a | 日本免费在线一区 | 成人伊人| 国产欧美一区二区久久 |